185 related articles for article (PubMed ID: 20407451)
21. Members need only apply.
Nat Biotechnol; 2011 Jul; 29(7):551. PubMed ID: 21747362
[No Abstract] [Full Text] [Related]
22. Collaboration may be the cure for what ails drug development.
Erickson AK
Nat Med; 2004 Jun; 10(6):558. PubMed ID: 15170189
[No Abstract] [Full Text] [Related]
23. Biotech jostles with pharma for slice of HIV market.
Katsnelson A
Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
[No Abstract] [Full Text] [Related]
24. Vertical integration: the drug industry and prescription benefits managers.
Gibaldi M
Pharmacotherapy; 1995; 15(3):265-71. PubMed ID: 7667161
[No Abstract] [Full Text] [Related]
25. Global update: Canada.
Willemse L; Isasi R; Lyall D
Regen Med; 2011 Nov; 6(6 Suppl):140-3. PubMed ID: 21999277
[TBL] [Abstract][Full Text] [Related]
26. The evolving role of collaboration in biotechnology.
Gower JM
Nat Biotechnol; 1998 May; 16 Suppl():31-2. PubMed ID: 9591261
[No Abstract] [Full Text] [Related]
27. Bye, bye blockbusters, hello niche busters.
Collier R
CMAJ; 2011 Aug; 183(11):E697-8. PubMed ID: 21690224
[No Abstract] [Full Text] [Related]
28. Where have all the investors gone?: the case for consolidation.
Esposito RS; Ostro MJ
Nat Biotechnol; 1998 May; 16 Suppl():63. PubMed ID: 9591277
[No Abstract] [Full Text] [Related]
29. Biotechnology partnerships--medicine for an ailing industry?
DeLamarter J
Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
[No Abstract] [Full Text] [Related]
30. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
Rea TS
Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
[No Abstract] [Full Text] [Related]
31. Opening up to precompetitive collaboration.
Altshuler JS; Balogh E; Barker AD; Eck SL; Friend SH; Ginsburg GS; Herbst RS; Nass SJ; Streeter CM; Wagner JA
Sci Transl Med; 2010 Oct; 2(52):52cm26. PubMed ID: 20926831
[TBL] [Abstract][Full Text] [Related]
32. No immediate pain relief for the pharmaceutical industry.
Ahlborn H; Henderson S; Davies N
Curr Opin Drug Discov Devel; 2005 May; 8(3):384-91. PubMed ID: 15892254
[TBL] [Abstract][Full Text] [Related]
33. The quiet revolution.
Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
[No Abstract] [Full Text] [Related]
34. Pharmaceutical sciences in 2020.
Crommelin D; Stolk P; Besançon L; Shah V; Midha K; Leufkens H
Nat Rev Drug Discov; 2010 Feb; 9(2):99-100. PubMed ID: 20118959
[No Abstract] [Full Text] [Related]
35. Opportunities for alliances between industry and pharmacy.
Rosenberg GB
Am J Hosp Pharm; 1994 Dec; 51(24):3061-5. PubMed ID: 7856627
[No Abstract] [Full Text] [Related]
36. Entry order as a consideration for innovation strategies.
Cohen FJ
Nat Rev Drug Discov; 2006 Apr; 5(4):285-93. PubMed ID: 16531989
[TBL] [Abstract][Full Text] [Related]
37. [Hungarian psychiatry today. Introduction].
Judit H
Psychiatr Hung; 2008; 23(4):221-3. PubMed ID: 19115571
[No Abstract] [Full Text] [Related]
38. Research & market strategy: how choice of drug discovery approach can affect market position.
Sams-Dodd F
Drug Discov Today; 2007 Apr; 12(7-8):314-8. PubMed ID: 17395091
[TBL] [Abstract][Full Text] [Related]
39. Innovation in health care: time for a gut check.
Salehizadeh B
Clin Gastroenterol Hepatol; 2012 Jan; 10(1):27-9. PubMed ID: 22177468
[No Abstract] [Full Text] [Related]
40. Biotech's wonder ride.
Rynecki D
Fortune; 2000 Mar; 141(5):435-6. PubMed ID: 10788046
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
